Trial Profile
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors (ACTengine IMA201-101)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2024
Price :
$35
*
At a glance
- Drugs IMA-201 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Carcinoma; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Acronyms ACTengine
- Sponsors Immatics US
- 18 Jan 2024 Status changed from active, no longer recruiting to completed.
- 21 Mar 2023 According to an Immatics N.V. media release, the company plans to discontinue this program after treatment of the remaining patients already enrolled in this trial in order to focus on its TCR Bispecific program TCER IMA401 addressing the identical target peptide derived from MAGEA4/8 as IMA201.
- 03 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Apr 2023.